CStone Pharmaceuticals

查看带有其 5 名主要高管的组织结构图

CStone Pharmaceuticals 搜索最多的简介

• Jason Yang, Chief Executive Officer
• Archie Tse, Chief Scientific Officer
• Jun Cheng, Vice President, Finance

创建提醒
跟踪 CStone Pharmaceuticals 的高管变动

CStone Pharmaceuticals 拥有 1,832 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Stemtech and Seacret Direct have announced they will merge  (公布2024十二月5号)..
• Recursion Pharma and Exscientia have merged  (公布2024十一月27号)..
• Stemtech and Seacret Direct have announced they will merge  (公布2024十一月22号)..

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

CStone Pharmaceuticals 的最新新闻稿

• Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting-CStone Pharmaceuticals
• CStone and Pharmalink Enter into Strategic Partnership for Sugemalimab in Middle East and North Africa Region and South Africa-CStone Pharmaceuticals
• CStone's CMO Dr. Qingmei Shi Attends World Companion Diagnostics & Liquid Biopsy Summit APAC, Shares Insights on Precision Medicine and Companion Diagnostics Co-development-CStone Pharmaceuticals
• CStone Presents Preclinical Data on CS2009 at the 2024 SITC Annual Meeting-CStone Pharmaceuticals
• CStone to Present Latest Clinical Data on CS5001 for Lymphoma at the 66th ASH Annual Meeting-CStone Pharmaceuticals
• CStone Announces Publication of Population Pharmacokinetics Modelling of Sugemalimab in British Journal of Clinical Pharmacology-CStone Pharmaceuticals
• CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK-CStone Pharmaceuticals
• CStone to Present Preclinical Data on CS2009 at the 2024 SITC Annual Meeting-CStone Pharmaceuticals
• CStone’s Partner Hengrui Initiates a Phase III Clinical Trial of Anti-CTLA-4-based Combination Therapy as First-line Treatment for Advanced Hepatocellular Carcinoma-CStone Pharmaceuticals
• CStone Announces Long-Term Survival Data for Sugemalimab (Cejemly®) in Combination with Platinum-based Chemotherapy as First-Line Treatment of Stage IV NSCLC at ESMO 2024-CStone Pharmaceuticals
• View more press releases Close

关于 CStone Pharmaceuticals 的社交媒体

• CStone Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• CStone Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Archie Tse

致电CStone Pharmaceuticals，电话：+1 512 ...

查看组织结构图

Register to receive your alert

报告错误